We are live on ! Find out more

Johnson & Johnson

JNJ

Market cap $654B

271.22 USD

+0.54

0.2%

At close Updated Sep 25, 4:00 PM EDT

Pre-market

After hours

272.00

+0.78

0.29%

1 day

0.2%

5 days

-0.19%

1 month

-0.7%

3 months

10.76%

6 months

13.04%

Year to date

30.8%

1 year

52.6%

5 years

66.22%

10 years

130.28%

About: Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Employees: 140,800

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 60.8%

Neutral 34.8%

Negative 4.4%

Neutral

24/7 Wall Street

1 day ago

Want Bulletproof Dividend Income? These 3 Stocks Have Raised Payouts Through 8 Major Downturns

Three companies have written dividend checks through stagflation, financial collapse, and a global pandemic without missing a single annual raise, but the headwinds each faces right now will test whether history really does repeat.

Positive

Seeking Alpha

1 day ago

Best Dividend Kings: September 2026

Dividend Kings are underperforming SPY in September, with a -4.22% average return versus SPY's marginal gain. Despite aggregate weakness, 29 Dividend Kings appear both undervalued and offer a long-term expected return of at least 10%. Recent dividend increases and higher projected earnings growth have modestly improved the Kings' average dividend growth rate to 4.49%.

Positive

The Motley Fool

2 days ago

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie continues to diversify its portfolio into neuroscience and aesthetics to offset the loss of patent exclusivity for older drugs. Johnson & Johnson maintains a massive presence in medical technology alongside its traditional innovative medicine development.

Positive

Benzinga

2 days ago

Johnson & Johnson Clinical Trials Show Progress Across Key Therapies

Johnson & Johnson (NYSE:JNJ) announced positive findings from key clinical evaluations testing its therapies, Tremfya and Carvykti, across psoriatic arthritis and multiple myeloma.

Neutral

24/7 Wall Street

2 days ago

ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade

AbbVie and Johnson and Johnson both trade near 52-week highs and carry decades of dividend raises, but one faces a patent cliff and a leveraged balance sheet that could force retirees to rethink their income strategy completely.

Positive

Proactive Investors

2 days ago

Johnson & Johnson says Tremfya eases spinal pain in Phase 4 psoriatic arthritis study

Johnson & Johnson (NYSE:JNJ) said its Tremfya treatment significantly improved spinal pain and stiffness in adults with axial psoriatic arthritis in a Phase 4 study. The company said Tremfya met the study's primary endpoint at week 24, showing greater improvement than placebo on a disease activity measure that includes spinal pain and stiffness.

Neutral

PRNewsWire

2 days ago

Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study

Topline results show TREMFYA met the primary and major secondary endpoints of axial involvement in PsA - including spinal pain and stiffness - and demonstrated significant improvement in MRI-confirmed inflammation First-ever study to use objective MRI assessments to confirm presence of axial involvement and demonstrate axial inflammation reduction in PsA SPRING HOUSE, Pa., Sept. 25, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that TREMFYA® (guselkumab) met the primary and major secondary endpoints demonstrating both improvement in axial symptoms and reduction in inflammation by MRI assessment in the Phase 4 STAR study evaluating biologic-naïve adults with active psoriatic arthritis and axial involvement (axial PsA).

Neutral

PRNewsWire

2 days ago

Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma

New results suggest earlier treatment may increase the likelihood of long-term remission Study adds to Johnson & Johnson's overwhelming body of evidence supporting its innovative multiple myeloma therapies in second line, where earlier intervention may increase long-term remission and disease control RARITAN, N.J., Sept. 25, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, announced today new long-term follow-up data from the initial subgroup of cohort A in the Phase 2 CARTITUDE-2 study (N=20) showing that 50% of patients (10/20) in early line relapsed or refractory multiple myeloma (RRMM) who were treated with a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) remained alive and progression-free for at least five years without maintenance therapy.1 These results build on the durable, treatment-free remissions observed in the CARTITUDE-1 study, which evaluated patients in later lines of therapy, and reinforce that earlier treatment with CARVYKTI® may increase long-term remission and disease control.

$Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma$